Viking Therapeutics Emerges as Key Player in Weight-Loss Drug Market

Viking Therapeutics has captured significant market attention with its recent stock performance, demonstrating strong upward momentum following analyst confirmation of what they describe as a “substantial price surge.” The biopharmaceutical company’s shares closed at $27.88 on Thursday, marking a solid 1.86 percent gain.

Dual-Approach Strategy Strengthens Market Position

The company’s metabolic disorder pipeline is generating considerable excitement, particularly its lead obesity candidate VK2735. Recent corporate updates from October 1 revealed important developmental milestones. The Phase 3 VANQUISH registration program for the injectable formulation is already underway, while the Phase 2 VENTURE trial for an oral tablet version has successfully achieved its primary endpoint.

This dual-approach strategy—offering both injectable and oral formulations—positions Viking competitively in the rapidly expanding weight-loss medication sector. Further expanding its metabolic portfolio, the company plans to submit an IND application for a new amylin agonist program during the fourth quarter of 2025.

Analyst Optimism and Acquisition Potential

Market researchers issued bullish assessments in late September and early October reports, highlighting compelling efficacy and safety data from Viking’s GLP-1 programs. VK2735 functions as a dual GLP-1/GIP agonist, utilizing the same mechanism as the most successful weight-loss medications currently available.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Adding to investor enthusiasm is Viking’s status as a potential acquisition target. Major pharmaceutical companies are actively seeking entry points into the booming metabolic market, and Viking’s independent position combined with its high-quality pipeline makes it an attractive candidate for merger and acquisition activity.

Upcoming Catalysts and Market Outlook

Attention now turns to October 22, when the company is scheduled to release its next quarterly report. Additional near-term milestones include the planned IND submission for the amylin program before year-end and continued progress updates from the Phase 3 VANQUISH studies, alongside further details about the oral VK2735 formulation.

The obesity treatment market continues to experience explosive growth, and Viking is establishing itself as a serious competitor to established industry leaders. The company’s strategy of developing both injectable and oral administration options could potentially capture significant market share in this expanding therapeutic area.